Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...
Pascal Soriot (pictured) topped up his basic salary of £1.8m with extras that included a bonus of £3.5m and share awards ...
Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the ...
AstraZeneca boss takes home £15m pay packet after profits rise - The Cambridge-based pharmaceutical company behind a variety ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that acquisition.< | ...
AstraZeneca has been hit with a US class action lawsuit that claims the UK’s largest listed company misled shareholders in connection with investigations by Chinese authorities.
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
Pascal Soriot, chief executive officer of the UK’s biggest drugmaker, was responding to reports that the company’s relationship with the new Labour government has soured, with Britain being ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
Astrazeneca has defended the £14.7 million pay package handed to chief executive Pascal Soriot, saying the group is too big ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results